Karthik Nath

Dr. Karthik Nath

Mater Research Institute - The University of Queensland, Translational Research Institute, Brisbane, QLD, Australia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2019 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
KNKarthik Nath
Karthik Nath
VGVibooshini Ganeshalingam
Vibooshini Ganeshalingam
BEBarbara Ewart
Barbara Ewart
EHElizabeth Heyer
Elizabeth Heyer
KWKerrianne Watt
Kerrianne Watt
GHGeorgina Hodges
Georgina Hodges

22 June 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
KNKarthik Nath
Karthik Nath
SLSoi-Cheng Law
Soi-Cheng Law
MSMuhammed B Sabdia
Muhammed B Sabdia
JGJay Gunawardana
Jay Gunawardana
LLLilia M. de Long
Lilia M. de Long
MGMaher Gandhi
Maher Gandhi
Data on the prognostic impact of pretherapy 18F-fluorodeoxyglucose–positron emission tomography (FDG-PET) in follicular lymphoma (FL) is conflicting. The predictive utility of pretherapy total metabolic tumor volume (TMTV) and maximum standardized uptake value (SUVmax) on outcome appears to vary between regimens. Chemoimmunotherapies vary in the extent of T-cell depletion they induce. The role of intratumoral T cells on pretherapy FDG-PET parameters is undefined. We assessed pretherapy FDG-PET parameters and quantified intratumoral T cells by multiple methodologies. Low intratumoral T cells associated with approximately sixfold higher TMTV, and FL nodes from patients with high TMTV showed increased malignant B-cell infiltration and fewer clonally expanded intratumoral CD8+ and CD4+ T-follicular helper cells than those with low TMTV. However, fluorescently labeled glucose uptake was higher in CD4+ and CD8+ T cells than intratumoral B cells. In patients with FDG-PET performed prior to excisional biopsy, SUVmax within the subsequently excised node associated with T cells but not B cells. In summary, TMTV best reflects the malignant B-cell burden in FL, whereas intratumoral T cells influence SUVmax. This may contribute to the contradictory results between the prognostic role of different FDG-PET parameters, particularly between short- and long-term T-cell–depleting chemoimmunotherapeutic regimens. The impact of glucose uptake in intratumoral T cells should be considered when interpreting pretherapy FDG-PET in FL.

4 November 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
NSNorah Layla Sadek
Norah Layla Sadek
BCBruno Almeida Costa
Bruno Almeida Costa
KNKarthik Nath
Karthik Nath
SMSham Mailankody
Sham Mailankody

6 August 2022 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
KNKarthik Nath
Karthik Nath
ATAna Alarcon Tomas
Ana Alarcon Tomas
JFJessica Flynn
Jessica Flynn
JFJoshua A. Fein
Joshua A. Fein
AAAnna Alperovich
Anna Alperovich
RSRoni Shouval
Roni Shouval
Vitamin D insufficiency is a potentially modifiable risk factor for poor outcomes in newly diagnosed large B-cell lymphoma (LBCL). However, the role of circulating vitamin D concentrations in relapsed/refractory LBCL treated with CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) is currently unknown. This was a single-center, observational study that evaluated the association of pre-CAR-T 25-hydroxyvitamin D (25-OHD) status with 100-day complete response, progression-free survival, overall survival, and CAR-T-related toxicity in 111 adult relapsed/refractory LBCL patients. Vitamin D insufficiency was defined as ≤30 ng/mL in accordance with the Endocrine Society guidelines. The median pre-CAR-T 25-hydroxyvitamin D concentration was 24 ng/mL (interquarile range = 18-34). Vitamin D-insufficient patients (≤30 ng/mL; n = 73 [66%]) were significantly younger than their vitamin D-replete (>30 ng/mL; n = 38 [34%]) counterparts (P= .039). The vitamin D-insufficient cohort was enriched for de novo LBCL as the histological subtype (P= .026) and had a higher proportion of tisagenlecleucel as the CAR-T product (P= .049). There were no other significant differences in the baseline characteristics between the two groups. In vitamin D-insufficient compared to -replete patients, 100-day complete response was 55% versus 76% (P= .029), and 2-year overall survival was 41% versus 71% (P= .061), respectively. In multivariate analysis, vitamin D insufficiency remained significantly associated with 100-day complete response (odds ratio 2.58 [1.05-6.83]; P= .045) and overall survival (hazard ratio 2.24 [1.08-4.66], P= .030). In recipients of tisagenlecleucel, vitamin D insufficiency was associated with significantly lower cell viability of the infused CAR-T product (P= .015). Finally, pretreatment vitamin D insufficiency did not predict for subsequent CAR-T-related toxicity. This is the first report to demonstrate that vitamin D insufficiency is associated with inferior clinical outcomes in CAR-T recipients. Further study into the mechanistic insights of this finding, and the potential role of vitamin D supplementation to optimize CAR-T are warranted.

1 August 2018 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
KNKarthik Nath
Karthik Nath
RBRachael Boles
Rachael Boles
AMAndrew McCutchan
Andrew McCutchan
VVVenkat Vangaveti
Venkat Vangaveti
ABAndrew Birchley
Andrew Birchley
IIIan Irving
Ian Irving

22 February 2021 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
KNKarthik Nath
Karthik Nath
MGMaher Gandhi
Maher Gandhi
Follicular lymphoma (FL) is the most common indolent B-cell lymphoma. Advanced stage disease is considered incurable and is characterized by a prolonged relapsing/remitting course. A significant minority have less favorable outcomes, particularly those with transformed or early progressive disease. Recent advances in our understanding of the unique genetic and immune biology of FL have led to increasingly potent and precise novel targeted agents, suggesting that a chemotherapy-future may one day be attainable. The current pipeline of new therapeutics is unprecedented. Particularly exciting is that many agents have non-overlapping modes of action, offering potential new combinatorial options and synergies. This review provides up-to-date clinical and mechanistic data on these new therapeutics. Ongoing dedicated attention to basic, translational and clinical research will provide further clarity as to when and how to best use these agents, to improve efficacy without eliciting unnecessary toxicity.